1,2 A note on UK access: Wegovy is approved and NICE-recommended for obesity, not for osteoarthritis specifically
It may be prescribed alone or combined with other medications such as bupropion (as in the branded combo Contrave), metformin, or GLP-1 medications like semaglutide or tirzepatide
FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026) In the published mouse studies, FOXO4-DRI caused no reported side effects: treated animals kept their weight, blood counts, and organ markers while senescent cells were cleared, and the peptide spared healthy cells in culture
Foundayo (orforglipron) There had been just one oral GLP-1 option for weight loss the Wegovy pill but the FDA just approved a second one in April 2026: Foundayo (orforglipron), manufactured by Eli Lilly and Company
Precision matters more than standardized assumptions
Brazilian evidence-based guidelines for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: a joint position statement from the Brazilian Society of En-docrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of obesity and metabolic syndrome (Abeso)